Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Allergy Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Allergy Other
    Itraconazole Benefits Patients With Severe Asthma, Sensitivity to Fungi - (DGNews)
    Allergies Alone Not Associated With Snoring, Daytime Sleepiness - (DGNews)
    Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study - (BMJ)
    ERRATUM: Pretreatment With Omalizumab Can Safely Increase Effectiveness of Immunotherapy: Presented at ACAAI - (DGDispatch)
    Antibodies to Cockroach, Mouse Proteins Associated With Asthma and Allergies in Preschool Children - (DGNews)

    News archive

     Recent webcasts/CME - Allergy Other
    New Perspectives on Allergy Management: Ophthalmologists and Allergists Weigh in on Key Issues
    Food Allergies: When the Food Comes to Bite the Gut

    Webcasts/CME archive

     Recent cases - Allergy Other
      Allergic Enterocolitis and Protein-Losing Enteropathy as the Presentations of Manganese Leak From an Ingested Disk Battery: A Case Report
      Successful Desensitization with Human Insulin in a Patient with an Insulin Allergy and Hypersensitivity to Protamine: A Case Report
      Milk Allergy and Bottles Over the Back Fence: Two Single Patient Trials
      Patch Test Triggering Recurrence of Distant Dermatitis: The Flare-Up Phenomenon
      Pigeon Fanciers Lung: A Case Report

      Cases archive
        




      my personal edition > allergy other > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Four-Injection Vaccine May Provide Ragweed Allergy Symptom Relief: Presented at ACAAI

      By Corinna S. Bowser, MD

      PHILADELPHIA, PA -- November 16, 2006 -- A vaccine approach to treating symptoms of ragweed allergy appears to be safe and effective, according to data presented here at the 2006 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI).

      The short-course allergy vaccine under investigation (Pollinex Quattro) incorporates monophosphoryl lipid A (MPL) TLR4 agonist adjuvant.

      Results of a study presented here on November 13th show that treatment with this vaccine relieved symptoms and increased specific immunoglobulin (Ig) G with no important safety issues noted over the course of the study.

      According to researcher Piyush Patel, MD, allergist in private practice, Mississauga, Ontario, Canada, the efficacy results appear to translate into improvements in quality of life for patients with ragweed allergy.

      "There is also a large postmarketing study, from its use in Europe, that shows it is very well tolerated, with a low incidence of local and systemic reactions," Dr. Patel said in an oral abstract presentation.

      The double-blind, placebo-controlled study included 177 ragweed-sensitive patients who underwent serial evaluations in an environmental exposure chamber that subjected them to controlled amounts of ragweed allergen.

      To establish baseline symptom scores, patients underwent 3-hour ragweed exposures on 4 consecutive days. Vaccine was given in 4 weekly injections at doses ranging from 300-6000 SU in 87 patients, while 90 patients received placebo injections. Exposure chamber assessments were repeated 3 weeks after the last injection for 3 hours on 4 consecutive days.

      Post-treatment reduction in total symptom score was -6.61 for treated patients and -4.47 for placebo (P = .007). In addition, increases in ragweed specific IgG level were significantly greater with the vaccine compared with placebo (3247.2 vs 36.6 ng/mL; P < .001).

      Levels of IgE were not significantly different between the treatment and placebo groups.

      Patient responses to the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) specific to the environmental exposure chamber used in the study showed that the vaccine group had greater improvement in both global assessments and practical problems, Dr. Patel said.

      Adverse events, which were mainly mild or moderate and related to injection site reactions, occurred in 153 patients. There were no severe adverse events.

      Phase 2 studies of this vaccine have been completed, and it is expected that phase 3 studies in ragweed and grass allergy will begin shortly. Allergy Therapeutics, the company developing the vaccine and sponsored the study, has said it expects to launch the allergy vaccine in the United States in 2009.

      [Presentation title: The Safety and Clinical Efficacy of Pollinex Quattro Ragweed Assessed in an Environmental Exposure Chamber. Abstract 22]




      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send